No animal studies with product; published murine and human TIL literature only
“No nonclinical studies were conducted with AMTAGVI. Instead, the applicant cited published nonclinical data evaluating similar murine and human tumor-derived T lymphocytes to provide support for AMTAGVI.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Why that species
Omission of tox studies accepted given product characteristics and biological activity (autologous unmodified T cells)
“No toxicology studies were conducted for AMTAGVI. Given the characteristics and biological activity of AMTAGVI, this omission is acceptable.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Surrogate molecule
Yes: published studies of similar murine (homologous) and human TILs used in lieu of product testing
“Instead, the applicant cited published nonclinical data evaluating similar murine and human tumor-derived T lymphocytes to provide support for AMTAGVI.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Species: general tox
None; no toxicology studies conducted (omission accepted)
“No toxicology studies were conducted for AMTAGVI. Given the characteristics and biological activity of AMTAGVI, this omission is acceptable.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Species: DART
Not conducted (product characteristics and biological activity)
“No DART studies were conducted for AMTAGVI. Given the characteristics and biological activity of AMTAGVI, this omission is acceptable.”
✓ VerifiedFDA pharmacology/toxicology review, p. 14Source ↗
Species: carcinogenicity
Not conducted; expanded TIL cultures free of tumor cells and residual tumor cells controlled at release
“No tumorigenicity studies were conducted for AMTAGVI. This is acceptable since Studies #3 and #4 provided evidence that the expanded human TIL cultures in the studies were free of tumor cells.”
✓ VerifiedFDA pharmacology/toxicology review, p. 14Source ↗
Surrogate used in
Yes: published data on similar murine and human tumor-derived lymphocytes used instead of product studies
“No nonclinical studies were conducted with AMTAGVI. Instead, the applicant cited published nonclinical data evaluating similar murine and human tumor-derived T lymphocytes to provide support for AMTAGVI.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗